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ABSTRACT. The reaction of the 3-oxo-N,3-diphenylpropan-amide (3) with either malononitrile or ethyl 
cyanoacetate in ammonium acetate gave the 1,2-dihydropyridine derivatives 6a or 6b, respectively. On the other 
hand, carrying the same reaction in the presence of triethylamine gave the 1,6-dihydropyridine derivatives 7a and 
7b, respectively. Moreover, compound 3 reacted with 2-aminoprop-1-ene-1,1,3-tricarbonitrile to give the pyridine 
derivative 9. Compound 7b reacted with the active methylene derivatives 10a,b and 4a,b to give the naphthyridine 
derivatives 11a,b and 12a,b; respectively. Compound 3 was also used for the synthesis of thiophene derivatives 
13a,b and 16a,b. In addition, the reaction of ethyl benzoylacetate (1) with o-phenylene diamine gave the 
benzimidazole derivative 18. The reactivity of the latter product towards different reagents was studied to give 
different products. The cytotoxicity of the newly synthesized products was studied towards some cancer and 
normal cell lines, in addition toxicity of compounds was measured and docking of the most active compounds was 
done. Compounds 6b, 7b, 9, 13a, 13b, 16a, 20b, 20c, 24b, 25 and 26b exhibited optimal cytotoxic effect against 
cancer tested cell lines. These active compounds were evaluated against c-Met kinase using foretinib as the 
reference drug where all compounds expressed higher activity than the reference drug. 
  




It is of great interest to note that pyridine and pyrimidine derivatives were one of the most 
classes of compounds due to their high pharmaceutical and biological values. Especially fused 
pyridine derivatives have varieties of biological uses. Among such activities, they are known to 
exhibit high pharmacological, CNS depressant [1, 2], neuroleptic [3] and tuberculostatic [4] 
activities. In addition, a largenumber of pyridines were used as antimicrobial agents [5], 
inhibitors of glycogen syntheses kinase-3 (GSK-3) [6] and potent antitumor agents [7]. 
Moreover, benzimidazoles represent a group of compounds with a large number of 
pharmaceutical applications and many of them were basic nucleus of drugs structures.  Some of 
them were naturally occurring nucleotides that capable to interact with biopolymers to enhance 
better biological properties. It was noticed that some 2-aminobenzimidazoles showed interesting 
antimicrobial effect, especially, their corresponding carbamate derivatives were obtained in 
good yields and exhibited significant in vivo antifilarial activity [8]. Within the field of drug 
designing such group of compounds have a great affinity towards different enzymes and protein 
receptors [9]. Optimization of benzimidazole-based structures has resulted in marketed drugs, 
e.g. within the field of chemotherapy it was found that omeprazole [10] and pimobendan [11] 
they were found not only as good therapeutically active drugs but also for treatment of heart 
feeler problems. Moreover, a large number of benzimidazoles derivatives are well known for 
their antimicrobial [12-15], anthelmintic [16], antiviral [17-18] and antifungal [19-21] activities. 
Many benzimidazole containing compounds are known as anticancer agents [22-28]. Within the 
field of topoisomerase inhibitors it was found that some benzimidazole was used as 
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topoisomerase inhibitory drugs, e.g. Hoechst 33258 and Hoechst 33342 (Figure 1) [29, 30]. 
Within the field of DNA binders, it was also found that bis-benzimidazole derivatiives are used 
as head to head binders [31]. Within the field of cancer chemotherapy, many drugs containing 
benzimidazole nucleus are known through the market like RAF265 (CHIR-265; Novartis 
Pharmaceuticals, Basel, Switzerland) and AZD6244 (ARRY-142886; AstraZeneca, London, 
England). A very active known drug is RAF265 resulted in a reduction in tumor cell growth and 
in tumor cell apoptosis [32].  
 
 
Figure 1. Examples of topoisomerase inhibitors containing benzimidazole nucleus. 
 
Due to such high importance of pyridine and benzimidazole derivatives was focused on the 
efficient synthesis of new pyridine and benzimidazole derivatives starting from ethyl 




13C NMR and 1H NMR spectra were recorded on Bruker DPX200 instrument in CDCl3 and 
DMSO with TMS as internal standard for protons and solvent signals as internal standard for 
carbon spectra. Chemical shift values are mentioned in δ (ppm). Mass spectra were recorded on 
EIMS (Shimadzu) and ESI-esquire 3000 Bruker Daltonics instrument. Elemental analyses were 
carried out by the Microanalytical Data Unit at Ludwig-Maximilians-Universität-München, 
Germany.  The progress of all reactions was monitored by TLC on 2 x 5 cm pre-coated silica gel 
60 F254 plates of thickness of 0.25 mm (Merck). 
 
General procedure for the synthesis of the 1,2-dihydropyridine derivatives 6a,b 
 
Either of malononitrile (0.66 g, 0.01 mol) or ethyl cyanoacetate (1.13 g, 0.01 mol) together with 
ammonium acetate (0.50 g) were added to a dry solid of compound 3 (2.16 g, 0.01 mol). The 
reaction mixture, in each case, was heated in an oil bath at 120 oC for 15 min. The solid product 
formed after boiling with ethanol was collected by filtration. 
 
6-Hydroxy-2-imino-1,4-diphenyl-1,2-dihydropyridine-3-carbonitrile (6a). Yellow crystals 
(EtOH), yield 74% (2.12 g), mp 119-121 oC. IR max cm
-1: 3544-3260, 3056, 2957, 2207, 1688, 
1662, 1604 (C=C). 1H NMR (DMSO-d6 400 MHz):  = 4.15 (s, 2H, CH2), 7.30-7.99 (m, 10H, 
2C6H5), 10.21 (s, 1H, NH). 
13C NMR (DMSO-d6 75 MHz):  = 49.5 (pyridine C-3), 103.6, 
104.5 (C=C), 119.5 (CN), 120.19, 121.3, 123.9, 124.1, 124.8, 125.2, 125.5, 126.0, 134.5, 136.8 
(two benzene, pyridine C), 165.9 (C=O), 175.2 (C=N). EIMS m/z 287 [M]+ (20); anal. calcd. for 
C18H13N3O (287.11): C, 75.25; H, 4.56; N, 14.63. Found: C, 72.06; H, 4.72; N, 14.88. 
 
Ethyl 6-hydroxy-2-imino-1,4-diphenyl-1,2-dihydropyridine-3-carboxylate (6b). Yellow crystals 
(EtOH), yield 70% (2.33 g), mp 277-279 oC. IR max cm
-1: 3443-3259, 3092, 2959, 2888, 1695, 
1689, 1636. 1H NMR (DMSO-d6 400 MHz):  = 1.14 (t, 3H, J = 7.03 Hz, OCH2CH3), 4,18 (q, 
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2H, J = 7.03 Hz, OCH2CH3),  5.95 (s, 2H, CH2), 7.30-7.99 (m, 10H, 2C6H5), 10.21 (s, 1H, D2O 
exchangeable, NH). 13C NMR (DMSO-d6  75 MHz) : 13.6 (OCH2CH3), 50.3 (OCH2CH3), 50.6  
(pyridine C-3), 103.8, 104.9 (C=C), 116.5 (CN), 119.0, 120.5, 122.5, 123.6, 124.4, 124.6, 125.1, 
125.7 (two benzene C), 163.8 (C=N), 165.1,  166.4 (2C=O), EIMS m/z 334 [M]+ (28). Anal. 
calcd. for C20H18N2O3 (334.38): C, 71.84; H, 5.43; N, 8.38 %. Found: C, 71.69; H, 5.51; N, 8.49. 
 
General procedure for the synthesis of the 1,6-dihydopyridine-2-carboxylate 7a,b 
 
Either malononitrile (0.66 g, 0.01 mol) or ethyl cyanoacetate (1.13 g, 0.01 mol) was added to a 
solution of compound 3 (2.16 g, 0.01 mol) in 1,4-dioxane (40 mL) containing triethylamine 
(0.50 mL). The reaction mixture, in each case was heated under reflux for 3 h then evaporated 
under vacuum. The solid product produced after triturating the remaining product with diethyl 
ether was collected by filtration. 
 
4-Amino-5-benzoyl-6-oxo-1-phenyl-1,6-dihydropyridine-2-carbonitrile (7a). Pale yellow 
crystals (1,4-dioxane), yield 80% (2.12 g), mp 160-168 oC. IR max cm
-1: 3544-3260, 3058, 
2957, 1705, 1689, 1632. 1H NMR (DMSO-d6 400 MHz):  = 4.28, 5.31 (2s, 4H, D2O 
exchangeable, 2NH2), 6.15 (s, 1H, pyridine H-4), 7.31-7.68 (m, 10H, 2C6H5). 
13C NMR 
(DMSO-d6 75 MHz):  = 119.5, 120.1, 120.7, 122.0, 123.6, 124.7, 125.6, 127.3, 129.8, 130.2, 
131.6, 139.4 (two benzene, pyridine C), 164.3, 166.4 (2 C=O). EIMS m/z 305 [M]+ (26). Anal. 
calcd. for C18H15N3O2 (305.54): C, 70.81; H, 4.95; N, 13.76.  
 
Ethyl 4-amino-5-benzoyl-6-oxo-1-phenyl-1,6-dihydropyridine-2-carboxylate (7b). Yellow 
crystals (1,4-dioxane), yield 81% (2.47 g), mp 177-179 oC. IR max cm
-1: 3540-3320, 3065, 
2955, 2889, 1718, 1688, 1633. 1H NMR (DMSO-d6 400 MHz): 4.25 (s, 2H, D2O 
exchangeable, NH2), 6.11 (s, 1H, pyridine H-4), 7.28-7.67 (m, 10H, 2C6H5), 11.42 (s, 1H, D2O 
exchangeable, OH). 13C NMR (DMSO-d6 75 MHz):  = 119.6, 120.2, 120.9, 122.5, 123.8, 
124.3, 124.6, 125.7, 129.8, 130.2, 133.2, 139.4 (two benzene, pyridine C), 164.2, 166.8 (2 
C=O). EIMS m/z 306.32 [M]+ (28). Anal. calcd. for C18H14N2O3 (306.32): C, 70.58; H, 4.61; N, 




2-Aminoprop-1-ene-1,1,3-tricarbonitrile (8) (1.32 g, 0.01 mol) was added to a solution of 
compound 3 (2.16 g, 0.01 mol) in 1,4-dioxane (40 mL) containing triethylamine (0.50 mL). The 
reaction mixture was heated under reflux for 6 h then evaporated under vacuum. The solid 
product produced after triturating the remaining product with diethyl ether was collected by 
filtration. Pale yellow crystals (1,4-dioxane), yield 86% (3.03 g), mp 260-263 oC. IR max cm
-1: 
3473, 3327, 3056, 2220, 1688, 1623. 1H NMR (DMSO-d6, 400 MHz)  = 4.92, 5.68 (2s, 4H, 
D2O exchangeable, 2NH2), 6.80 (s, 1H pyridine H-6), 7.31-7.58 (m, 10H, 2C6H5). 
13C NMR 
(DMSO-d6, 75 MHz):  = 116.8 (CN), 120.1, 121.3, 122.3, 123.5, 124.0, 124.8, 125.1, 126.4, 
128.1, 130.2, 131.2, 131.8, 133.2, 134.2 (two C6H5, two pyridine C), 162.4 (C=O), 169.5 (C=N).  
EIMS m/z 353 [M]+ (22). Anal. calcd. for C21H15N3O (353.39): C, 71.38; H, 4.28; N, 19.82. 
Found: C, 71.42; H, 4.31; N, 19.72. 
 
General procedure for the synthesis of the 1,6-naphthridine derivatives 11a,b 
 
Either acetylacetone (1.00 g, 0.01 mol) or ethyl acetoacetate (1.30 g, 0.01 mol) was added to a 
solution of compound 7b (3.06 g, 0.01 mol) in 1,4-dioxane (40 mL) containing triethylamine 
(0.50 mL). The reaction mixture was heated under reflux for 4 h then poured onto ice/water and 
the formed solid product was collected by filtration.  
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8-Benzoyl-2,4-dimethyl-6-phenyl-1,6-naphthridine-5,7(1H,6H)-dione (11a). Orange crystals 
(1,4-dioxane) yield 76% (2.81 g), mp 116-118 oC. IR max cm
-1: 3430-3261, 3065, 2919, 1688-
1662. 1H NMR (DMSO-d6 400 MHz)  = 2.51, 4.1 (2s, 6H, 2CH3), 5.95 (s, 1H, pyridine H-3), 
7.25-7.54 (m, 10H, 2C6H5), 10.16 (s, 1H, D2O exchangeable, NH). 
13C NMR (DMSO-d6 75 
MHz) : 39.6, 49.8 (2 CH3), 119.9, 120.0, 123.9, 124.2, 124.8, 125.8, 126.0, 126.3, 129.3.2, 
129.4, 130.6, 132.6, 134.1, 134.2 (two benzene C, two pyridine C), 165.8, 170.2, 175.2 (3 
C=O). EIMS m/z 370 [M]+ (20). Anal. calcd. for C23H18N2O3 (370.41): C, 74.58; H, 4.90; N, 
7.56.  Found: C, 74.66; H, 4.69; N, 7.38. 
 
8-Benzoyl-4-hydroxy-2-methyl-6-phenyl-1,6-naphthridine-5,7(1H,6H)-dione (11b). Yellow 
crystals (1,4-dioxane), yield 80% (2.97 g), mp 97-99 oC. IR max cm
-1: 3550-3320, 3055, 2955, 
2889, 1720-1688, 1633. 1H NMR (DMSO-d6 400 MHz)  = 2.51 (s, 3H, CH3), 5.45 (s, 1H, 
pyridine H-3), 7.01-7.31 (m, 10H, 2C6H5), 8.20 (s, 1H, D2O exchangeable, NH), 9.01 (s, 1H, 
D2O exchangeable, OH). 
13C NMR (DMSO-d6 75 MHz) : 25.1, (CH3), 118.9, 119.8, 120.3, 
123.6, 123.9, 124.2, 125.3, 125.6, 128.6, 129.4, 132.1, 133.6, 134.2, 134.6 (two benzene, two 
pyridine C), 165.6, 172.0, 180.3 (3 C=O). EIMS m/z 372 [M]+ (18). Anal. calcd. for C22H16N2O4 
(372.38): C, 70.96; H, 4.33; N, 7.52. Found: C, 70.82; H, 4.48; N, 7.63. 
 
General procedure for the synthesis of the 5,6,7,8-tetrahydro-1,6-naphthyridine derivatives 
12a,b 
 
Either malononitrile (0.66 g, 0.01 mol) or ethyl cyanoacetate (1.13 g, 0.01 mol) was added to a 
solution of compound 7b (3.06 g, 0.01 mol) in 1,4-dioxane (40 mL) containing triethylamine 
(0.50 mL). The reaction mixture was heated under reflux for 8 h then poured onto ice/water and 
the formed solid product was collected by filtration. 
 
2-Amino-5,7-dioxo-4,6-diphenyl-5,6,7,8-tetrahydro-1,6-naphthyridine-3-carbonitrile (12a). 
Yellow crystals (1,4-dioxane), yield 88% (3.11 g), mp 140-143 oC. IR max cm
-1: 3409-3334, 
3055, 2923, 2210, 1680-1662. 1H NMR (DMSO-d6 400 MHz): = 3.58, 4.20 (2s, 4H, D2O 
exchangeable, 2NH2), 6.20 (s, 1H, pyridine H-3), 7.20 (s, 1H, pyridine H-3), 7.27-7.54 (m, 10H, 
2C6H5). 
13C NMR (DMSO-d6 75 MHz) : 48.9 (pyridine C-3), 119.9, 120.3, 120.6, 123.9, 125.8, 
128.6, 129.3.2, 129.4, 132.6, 134.1, 140.4 (two benzene C, two pyridine C), 165.8, 166.3, 170.1 
(3 C=O), 195.3 (C=N). EIMS m/z 372[M]+ (20); anal. calcd. for C21H16N4O3 (372.38): C, 67.73; 
H, 4.33; N, 15.05. Found: C, 67.58; H, 4.04; N, 15.25. 
 
2-Hydroxy-5,7-dioxo-4,6-diphenyl-5,6,7,8-tetrahydro-1,6-naphthyridine-3-carbonitrile (12b). 
Yellow crystals (1,4-dioxane), yield 70% (2.48 g), mp 100-103 oC. IR max cm
-1: 3542-3260, 
3093, 2956, 1688-1662, 1605. 1H NMR (DMSO-d6 400 MHz)  = s, 2H, D2O 
exchangeable, NH2), 4.14 (s, 1H, pyridine H-3), 7.27-7.67 (m, 11H, 2C6H5, pyridine H-3), 10.19 
(s, 1H, D2O exchangeable, OH). 
13C NMR (DMSO-d6 75 MHz)  = 49.5 (pyridine C-3), 119.8, 
120.2, 122.5, 123.6, 124.2, 124.6, 125.3, 125.8, 130.2, 132.5, 133.2, 134.1, 134.6. 135.2 (two 
benzene C, two pyridine C), 165.6, 170.1 (2C=O), 171.1 (C=N). EIMS m/z 373 [M]+ (20). Anal. 
calcd. for C21H15N3O4 (373.37): C, 67.56; H, 4.05; N, 11.25. Found: C, 67.33; H, 3.87; N, 11.41. 
General procedure for the synthesis of the thiophene derivatives 13a,b 
Each of elemental sulfur (0.32 g, 0.01 mol) and either malononitrile (0.66 g, 0.01 mol) or ethyl 
cyanoacetate (1.13 g, 0.01 mol) was added to a solution of compound 3 (2.16 g, 0.01 mol) in 
1,4-dioxane (40 mL) containing triethylamine (0.50 mL). The reaction mixture, in each case, 
was heated under reflux for 3 h then poured onto ice/water containing few drops of hydrochloric 
acid and the formed solid product was collected by filtration. 
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5-Amino-4-cyano-N,3-diphenylthiophene-2-carboxamide (13a). Orange crystals (1,4-dioxane), 
yield 90% (2.87 g), mp 120-122 oC. IR max cm
-1:3439-33259, 3056, 2923, 2211, 1687. 1H 
NMR (DMSO-d6 400 MHz):  = 4.15 (s, 2H, D2O exchangeable, NH2), 7.31-7.58 (m, 10H, 
2C6H5), 10.21 (s, 1H, D2O exchangeable, NH), .
13C NMR (DMSO-d6 75 MHz):  = 117.5 (CN),  
120.3, 121.6, 122.8, 123.6, 124.4, 124.8, 125.1, 125.8, 136.7, 139.5. 140.4, 142.2 (two benzene 
C, thiophene C), 165.8 (C=O). EIMS m/z 319 [M]+ (26). Anal. calcd. for C18H13N3OS (319.38): 
C, 67.69; H, 4.10; N, 13.16; S, 10.04. Found: C, 67.56; H, 3.89; N, 12.88; S, 10.38. 
 
Ethyl 2-amino-4-phenyl-5-(phenylcarbamoyl)thiophene-3-carboxylate (13b). Orange crystals 
(1,4-dioxane), yield 73% (2.67 g), mp 90-93 oC. IR max cm
-1: 3426-3261, 3056, 2955, 2890, 
1687-1661, 1604 (C=C). 1H NMR (DMSO-d6 400 MHz)  = tJHz, 
OCH2CH3, 4.18 (q, 2H, J = 6.09 Hz, OCH2CH3),(s, 2H, D2O exchangeable, NH2), 7.31-
7.99 (m, 10H, 2C6H5),  10.01 (s, 1H, D2O exchangeable, NH). 
13C NMR (DMSO-d6 75 MHz) : 
16.5 (OCH2CH3), 50.2 (OCH2CH3), 119.4, 119.9, 121.9, 123.8, 124.6, 125.1, 125.5, 126.2, 
132.3, 133.1, 134.6, 135.3 (two C6H5, thiophene C), 165.8, 167.1 (2C=O). EIMS m/z 366 [M]
+ 
(28). Anal. calcd. for C20H18N2O3S (366.43): C, 65.55; H, 4.95; N, 7.64; S, 8.75. Found: C, 
65.72; H, 4.73; N, 7.73; S, 8.93. 
 
General procedure for the synthesis of the 4-(phenylcarbamoyl)thiophene derivatives 16a,b 
 
To a solution of compound 2 (2.39 g, 0.01 mol) in dimethylformamide (30 mL) containing 
potassium hydroxide (0.56 g, 0.01 mol) phenylisothiocyanate was added. The reaction mixture 
was stirred at room temperature for 24 h then to the reaction mixture either ethyl chloroacetate 
(1.22 g, 0.01 mol) or (0.92 g, 0.01 mol) was added. The reaction mixture was stirred at room 
temperature for an additional 24 h then poured onto ice/water containing few drops of 
hydrochloric acid (till pH 6) and the formed solid product was collected by filtration. 
 
Ethyl 3-phenyl-5-(phenylamino)-4-(phenylcarbamoyl)thiophene-2-carboxylate (16a). Yellow 
crystals (1,4-dioxane), yield 86% (3.80 g), mp 160-163 oC. IR max cm
-1: 3397-3229, 3048, 
2986, 2890, 1688-1668, 1624. 1H NMR (DMSO-d6 400 MHz)  = tJHz, 
OCH2CH33.87(q, 2H, J = 7.21 Hz, OCH2CH3)7.43-7.49 (m, 15H, 3C6H5),  8.20, 10.39 (2s, 
2H, D2O exchangeable, 2NH). 
13C NMR (DMSO-d6 75 MHz)  = 16.6 (OCH2CH3), 50.6 
(OCH2CH3), 120.0, 121.8, 122.6, 123.8, 123.9, 124.2, 124.5, 125.2, 125.3, 125.8, 126.3, 126.9, 
130.4, 133.1, 138.0, 139.2 (three C6H5 and thiophene C), 165.8, 167.1 (2C=O). EIMS m/z 366 
[M]+ (28). Anal. calcd. for C26H22N2O3S (442.53): C, 70.57; H, 5.01; N, 6.33; S, 7.24. Found: C, 
70.29; H, 4.87; N, 6.58; S, 7.42. 
 
5-Methyl-N,4-diphenyl-2-(phenylamino)thiophene-3-carboxamide (16b). Orange crystals (1,4-
dioxane), yield 79% (3.25 g), mp 175-177 oC. IR max cm
-1: 3453-3422, 3054, 2932, 1720-1668. 
1H NMR (DMSO-d6 400 MHz):  = 3.56 (s, 3H, CH3), 7.24-7.56 (m, 15H, 3C6H5), 10.51, 11.30 
(2s, 2H, D2O exchangeable, 2NH). 
13C NMR (DMSO-d6 75 MHz) : 16.6 (CH3), 119.2, 120.5, 
120.8, 121.2, 121.7, 122.5, 123.6, 123.8, 124.8, 125.3, 125.6, 126.2, 130.4, 132.5, 133.8, 134.1 
(three benzene C, thiophene C), 167.8, 172.5 (2C=O). EIMS m/z 412 [M]+ (20). Anal. calcd. for 





Equimolar amounts of ethyl benzoylacetate (1.92 g, 0.01 mol) and o-phenylenediamine (1.09 g, 
0.01 mol) were heated at 120 oC in the dry conditions in an oil bath for 10 min then the reaction 
mixture was left to cool. The formed solid product was triturated with diethylether then 
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collected by filtration.  Pale yellow crystals (1,4-dioxane), yield 72% (1.69 g), mp  180-183 oC. 
IR max cm
-1: 3437-3302, 3053, 2974, 1680, 1615. 1H NMR (DMSO-d6 400 MHz):  = 3.50 (s, 
2H, CH2), 7.20-7.55 (m, 9H, C6H5, C6H4), 10.45 (s, 1H, D2O exchangeable, NH). 
13C NMR 
(DMSO-d6 75 MHz): = 49.8 (CH2), 118.2, 123.8, 124.9, 125.0, 125.3, 126.0, 126.4, 126.8, 
128.3, 129.6 (benzene, indole C), 164.8 (C=O), 167.2 (C=N). EIMS m/z 236 [M]+ (90). Anal. 
calcd. for C15H12N2O (236.27): C, 76.25; H, 5.12; N, 11.86. Found: C, 76.39; H, 4.82; N, 11.66. 
 
General procedure for the synthesis of the benzo[d]imidazol derivatives 20a-c 
 
Either  benzaldehyde (1.06 g, 0.01 mol) 4-methoxybanzaldehyde  (1.36 g, 0.01 mol) or 4-
chlorobenzaldehyde (1.40 g, 0.01 mol) was added to  a solution of compound 18 (2.36 g, 0.01 
mol) in 1,4-dioxane (40 mL) containing piperidine (0.50 mL). The reaction mixture, in each 
case, was heated under reflux for 3 h then poured onto ice/water containing few drops of 
hydrochloric acid. The formed oily product was triturated with ethanol and the precipitated 
product was collected by filtration. 
 
2-(1H-Benzo[d]imidazol-2-yl)-1,3-diphenylprop-2-en-1-one  (20a). Pale yellow crystals (1,4-
dioxane), yield 68% (2.20 g), mp 183-187 oC. IR max cm
-1: 3537-3425, 3053, 1680, 1615. 1H 
NMR (DMSO-d6 400 MHz):  = 6.06 (s, 1H, CH), 7.26-7.55 (m, 14H, 2C6H5, C6H4), 10.54 (s, 
1H, D2O exchangeable NH). 
13C NMR (DMSO-d675 MHz) :  85.1, 112.3 (C=C), 120.3, 122.2, 
122.6, 123.1, 123.5, 124.0, 124.6, 125.0, 125.4, 125.7, 127.5, 127.3 (2C6H5, C6H4), 160.2 (CO), 
173.4 (C=N). EIMS m/z 324[M]+ (48); anal. calcd. for C22H16N2O (324.38): C, 81.46; H, 4.97; 
N, 8.64.   Found: C, 81.66; H, 5.26; N, 8.47.  
 
2-(1H-Benzo[d]imidazol-2-yl)-3-(4-methoxyphenyl)-1-phenylprop-2-en-1-one (20b). Orange 
crystals (1,4-dioxane), yield 78% (2.76 g), mp  145-147 oC. IR max cm
-1: 3424-3244, 3058, 
1710, 1666. 1H NMR (DMSO-d6 400 MHz)  = 3.50 (s, 3H, CH3), 6.08 (s, 1H, CH), 7.26-7.55 
(m, 13H, C6H5, 2C6H4), 10.54 (s, 1H, D2O exchangeable NH). 
13C NMR (DMSO-d6 75 MHz) : 
38.7 (CH3), 89.2, 113.8 (C=C), 120.1, 122.4, 122.7, 123.0, 123.3, 124.1, 124.5, 125.2, 125.8, 
125.3, 127.1, 127.2 (C6H5. 2C6H4), 161.2 (CO), 172.8 (C=N). EIMS m/z 354 [M]
+ (25). Anal. 
calcd. for C23H18N2O2 (354.41): C, 77.95; H, 5.12; N, 7.90. Found: C, 78.28; H, 5.08; N, 8.21. 
 
2-(1H-Benzo[d]imidazol-2-yl)-3-(4-chlorophenyl)-1-phenylprop-2-en-1-one (20c). Yellow 
crystals (1,4-dioxane), yield 72% (2.57 g), mp 160-163 oC. IR max cm
-1: 3423-3294, 3055, 
1720, 1660. 1H NMR (DMSO-d6 400 MHz)  = 6.08 (s, 1H, CH), 7.26-7.55 (m, 13H, C6H5, 
2C6H4), 10.54 (s, 1H, D2O exchangeable NH). 
13C NMR (DMSO-d6 75 MHz) = 87.3, 112.6 
(C=C), 119.2, 122.4, 122.9, 123.0, 123.3, 124.2, 124.8, 125.3, 125.9, 126.1, 127.7, 128.6 (C6H5. 
2C6H4), 161.4 (CO), 171.3 (C=N). EIMS m/z 358 [M]
+ (38); anal. calcd. for C22H15ClN2O 
(358.83): C, 73.64; H, 4.21; N, 7.81. Found: C, 73.75; H, 4.52; N, 7.95. 
 
2-(3,5-Diphenyl-1H-pyrazol-4-yl)-1H-benzo[d]imidazole (21)  
 
To a solution of compound 20a (3.24 g, 0.01 mol) in 1,4-dioxane (40 mL) hydrazine hydrate 
(0.50 g, 0.01 mol) was added. The reaction mixture was heated under reflux for 2 h then poured 
onto ice/water containing few drops of hydrochloric acid and the formed solid product was 
collected by filtration. Yellow crystals (EtOH), yield 68% (2.28 g), mp 221-223 oC. IR max   
cm-1: 3440-3302, 3054, 1662, 1608. 1H NMR (DMSO-d6 400 MHz)  = 7.28-7.74 (m, 14H, 
2C6H5, C6H4), 10.12, 11.20 (2s, 2H, D2O exchangeable, 2NH), 
13C NMR (DMSO-d6 75 MHz) : 
118.3, 121.5, 121.9, 122.6, 123.8, 124.3, 124.5, 125.8, 126.0, 126.2, 127.6, 130.6, 139.2, 140.4 
(2C6H5, C6H4, pyrazole C), 163.4, 170.0 (two C=N). EIMS m/z 336 [M]
+ (66); anal. calcd. for 
C22H16N4  (336.40): C, 78.55; H, 4.79; N, 16.66. Found: C, 78.39; H, 4.86; N, 16.41. 
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Malononitrile (0.66 g, 0.01 mol) was added to a solution of compound 20b (3.54 g, 0.01 mol) in 
1,4-dioxane  (40 mL) containing triethylamine (0.50 mL). The reaction mixture was heated 
under reflux for 4 h then evaporated under vacuum. The remaining product was triturated with 
ethanol and the formed solid product was collected by filtration. Yellow crystals (EtOH), yield 
73% (3.05 g), mp 182-185 oC. IR max cm
-1: 3438-3304, 3054, 2200, 1687, 1662, 1614. 1H NMR 
(DMSO-d6 400 MHz)  = 3.50 (s, 3H, OCH3), 5.02 (s, 2H, D2O exchangeable, NH2), 7.21-7.55 
(m, 13H, C6H5, 2C6H4), 
13C NMR (DMSO-d6 75 MHz) : 46.8 (OCH3), 116.9 (CN), 120.3, 
120.6, 121.5, 121.8, 122.3, 123.2, 123.7, 124.7, 124.8, 125.0, 125.5, 126.7, 130.4, 131.6, 137.7, 
139.9 (C6H5, 2C6H4, pyridine C), 163.2 (C=O), 166.8  (C=N). EIMS m/z 418 [M]
+ (48); anal. 
calcd. for C26H18N4O2 (418.54): C, 74.63; H, 4.34; N, 13.39. Found: C, 74.49; H, 4.62; N, 13.61. 
 
General procedure for the synthesis of the arylhydrazone derivatives 24a,b 
 
To a cold solution (0-5 oC) of compound 18 (2.36 g, 0.01 mol) in ethanol (50 mL) containing 
sodium acetate (3.50 g, 0.50 mol) either benzenediazonium chloride (0.01 mol) or 4-chloro- 
benzenediazonium chloride (0.01 mol [prepared by adding a cold solution of sodium nitrite 
(0.70 g, in water (10 mL)) to a cold solution (0-5 oC) of either aniline (0.93 g, 0.01 mol) or 4-
chloroaniline (1.27 g, 0.01 mol) in concentrated hydrochloric acid (12 mL) with continuous 
stirring] was added with continuous stirring. The whole reaction mixture was left at room 
temperature for 1 h then, the formed solid product was collected by filtration.  
 
2-(1H-Benzo[d]imidazol-2-yl)-1-phenyl-2-(2-phenylhydrazono)ethanone (24a). Orange crystals 
(EtOH), yield 88% (2.99 g), mp 167-169 oC. IR max cm
-1: 3440-3299, 3053, 1668, 1610. 1H 
NMR (DMSO-d6 400 MHz)  = 7.26-7.55 (m, 14H, 2C6H5, C6H4), 8.05, 10.55 (2s, 2H, D2O 
exchangeable, 2NH). 13C NMR (DMSO-d6 75 MHz) : 121.0, 121.4, 122.6, 123.1, 123.5, 124.2, 
124.6, 125.0, 125.3, 126.0, 128,2, 128.4, 130.4, 130.9, 137.7, 139.9 (2C6H5, C6H4), 163.0 
(C=O), 166.8, 168.4  (2C=N). EIMS m/z 340 [M]+ (28); anal. calcd. for C21H16N4O(340.13): C, 
74.10; H, 4.74; N, 16.46. Found: C, 74.33; H, 4.59; N, 16.79. 
 
2-(1H-Benzo[d]imidazol-2-yl)-1-phenyl-2-(2-(4-chlorophenylhydrazono)ethanone (24b). 
Orange crystals from (EtOH), yield 80% (2.99 g), mp 155-157 oC. IR max cm
-1: 3442-3302, 
3055, 1666, 1610. 1H NMR (DMSO-d6 400 MHz)  = 7.26-7.58 (m, 13H, C6H5, 2C6H4), 8.08, 
10.55 (2s, 2H, D2O exchangeable, 2NH). 
13C NMR (DMSO-d6 75 MHz) : 120.4, 121.3, 122.7, 
123.3, 123.8, 124.0, 124.4, 125.1, 125.5, 126.4, 128.1, 128.5, 130.7, 130.4, 138.2, 139.5 (C6H5, 
2C6H4), 163.2 (C=O), 166.8, 168.6 (2C=N). EIMS m/z 374 [M]
+ (56). Anal. calcd. for 




Malononitrile (0.66 g, 0.01 mol) was added to a solution of compound 18 (2.36 g, 0.01 mol) or 
3b (2.30 g, 0.01 mol) in 1,4-dioxane (40 mL) containing triethylamine  (0.50 mL). The reaction 
mixture was heated under reflux for 4 h then poured onto ice/water and the formed solid product 
was collected by filtration. Yellow crystals (EtOH), yield 75% (2.26 g), mp 190-193 oC. IR max 
cm-1: 3426-3201, 3055, 1670, 1570. 1H NMR (DMSO-d6 400 MHz)  = 4.10, 5.40 (2s, 4H, D2O 
exchangeable, 2NH2), 7.26-7.55 (m, 10H, C6H5, C6H4, pyridine H-3). 
13C NMR (DMSO-d6 75 
MHz)  = 116.2, 120.3, 120.4, 121.1, 122.3, 122.7, 123.5, 123.9, 124.8, 128.1, 128.6, 130.4, 
142,3, 142.6, 152.6  (C6H5, C6H4, pyridine C), 165.7  (C=O), 171.3 (C=N). EIMS: m/z = 302 
[M]+ (24); anal. calcd. for C18H14N4O (302.34): C, 71.51; H, 4.67; N, 18.53. Found: C, 71.39; H, 
4.48; N, 18.71. 
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General procedure for the synthesis of the benzo[4,5]imidazo[1,2-a]pyridine derivatives 26a,b 
 
Either acetylacetone (1.0 g, 0.01 mol) or ethyl acetoacetate (1.30 g, 0.01 mol) to a solution of 
compound 18 (2.36 g, 0.01 mol) in 1,4-dioxane (40 mL) containing triethylamine (0.50 mL). 
The reaction mixture was heated under reflux for 2 h then poured onto ice/water and the formed 
solid product was collected by filtration.  
 
(1,3-Dimethylbenzo[4,5]imidazo[1,2-a]pyridine-4-yl)(phenyl)methanone (26a). Yellow crystals 
(EtOH), yield 68% (2.10 g), mp 130-133 oC. IR max cm
-1: 3058, 1720, 1620. 1H NMR (DMSO-
d6 400 MHz)  = 2.42, 3.34 (2s, 6H, 2CH3), 6.61 (s, 1H, pyridine H-3), 7.27-7.36 (m, 9H, C6H5, 
C6H4).  
13C NMR (DMSO-d6 75 MHz)  = 24.3, 26.2 (2CH3), 118.6, 121.4, 121.8, 123.5, 124.5, 
125.3, 125.8, 126.1, 127,3, 129.2, 130.4, 140.5, 143.0, 150.3 (C6H5, C6H4, pyridine C), 165.5  
(C=O), 167.2 (C=N). EIMS m/z 300 [M]+ (68). Anal. calcd. for C21H16N4O (300.36): C, 79.98; 
H, 5.37; N, 9.33. Found: C, 79.69; H, 5.48; N, 9.59. 
 
1-Hydroxy-3-methylbenzo[4,5]imidazo[1,2-a]pyridine-4-yl)(phenyl)methanone (26b). Orange 
crystals (EtOH), yield 77% (2.32 g), mp 145-147 oC. IR max cm
-1: 3435-3125, 3058, 1696, 
1474. 1H NMR (DMSO-d6 400 MHz) = 3.34 (s, 3H, CH3), 6.63 (s, 1H, pyridine H-3), 7.27-
7.38 (m, 9H, C6H5, C6H4), 10.50 (s, 1H, D2O exchangeable, OH). 
13C NMR (DMSO-d6 75 MHz) 
 = 24.1 (CH3), 119.2, 122.0, 122.8, 123.1, 123.5, 124.7, 125.2, 126.3, 127.3, 129.2, 132.6, 
142.1, 143.0, 144.6 (C6H5, C6H4, pyridine), 166.4 (C=O), 168.2 (C=N). EIMS m/z 302 [M]
+ 





Chemical used through the anticancer evaluations of the synthesised compounds were obtained 




The cancer cell lines namely the human gastric cancer (NUGC and HR), human colon cancer 
(DLD1), human liver cancer (HA22T and HEPG2), human breast cancer (MCF), 
nasopharyngeal carcinoma (HONE1) and normal fibroblast cells (WI38) were kindly provided 
by the National Cancer Institute (NCI, Cairo, Egypt). The cytotoxicity of the newly synthesised 
compounds against the six cancer cell lines and the normal fibroblast were demonstrated 
through Table 1.  
 
c-Met enzymatic activity of the most active compounds 
 
Using homogeneous time-resolved fluorescence (HTRF) assay as previously reported the c-Met 
kinase activities of compounds 6b, 7b, 9, 13a, 13b, 16a, 20b, 20c, 24b, 25 and 26b were 
evaluated. The IC50’s were expressed through Table 2 using foretinib as the positive control. 
The data revealed that the three compounds expressed high enzymatic activity toward c-Met 
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Cytotoxocity (IC50 in nM) 
NUGC DLDI HA22T HEPG2 HONE1 MCF WI38 
6a 2140 3228 2314 2230 3219 2240 na 
6b 66 80 238 232 470 128 na 
7a 2201 1488 2150 2068 3188 2146 na 
7b 380 120 114 1340 666 1504 na 
9 222 360 1128 2134 1240 1280 na 
11a 2210 2395 1163 1446 1178 3430 na 
11b 1320 1348 129 330 2177 2166 na 
12a 3270 2870 2244 1252 1049 2271 na 
12b 1282 1320 1160 870 1140 1160 na 
13a 860 1028 759 1025 1254 1220 na 
13b 750 539 1220 299 1186 1228 380 
16a 182 268 560 2028 1130 328 na 
16b 1135 1062 1011 1210 466 210 na 
18 2220 2440 1128 2432 2143 2056 na 
20a 1240 1562 1063 1260 1619 1655 na 
20b 480 682 1158 1324 1460 1603 na 
20c 330 268 98 64 1209 332 na 
21 2262 2152 1381 1060 1313 1145 na 
22 1080 150 840 324 360 1246 665 
24a 1149 2160 3261 2136 2484 2868 na 
24b 380 122 33 669 1240 890 na 
25 487 350 3340 229 82 262 na 
26a 1445 3110 3013 3076 670 2742 na 
26b 32 48 260 82 71 559 na 
CHS 828 25 2315 2067 1245 15 18 na 
aNUGC, gastric cancer, DLDI, colon cancer, HA22T, liver cancer, HEPG2, liver cancer; HONEI, nasopharyngeal 
carcinoma; HR, gastric cancer; MCF, breast cancer; WI38, normal fibroblast cells. 
 
Table 2. c-Met enzymatic activity of the most active compounds. 
 
Compound No. IC50 (nM) c-Met 
6b 0.24 ± 0.05 
7b 0.36 ± 0.28 
9 0.42 ± 0.16 
13a 0.58 ± 0.28 
13b 0.61 ± 0.31 
16a 0.48 ± 0.19 
20b 0.53 ± 0.20 
20c 0.86 ± 0.45 
24b 0.50 ± 0.28 
25 0.73 ± 0.25 
26b 0.80 ± 0.32 
 Foretinib1.16 ± 0.17 
 
RESULTS AN DISCUSSION  
The present investigation emphasized mainly on two important things, of these one is to the 
synthesis of  molecules having  nitrogen and or sulfur  heterocyclic and the other is to determine  
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Scheme 1. Synthesis of compounds 6a,b; 7a,b and 9. 
 
their cytotoxicity against cancer and normal cell lines. The synthetic strategies adopted for the 
synthesis of the intermediates and target compounds are depicted in Schemes 1-4. Nitrogen 
containing heterocyclic organic compounds having extra keto group show interesting chemical 
properties as well as biological activity [33]. The reaction of ethyl benzoylacetate (1) with 
aniline (2) gave the 3-oxo-N,3-diphenylpropanamide (3). Compound 3 reacted with either 
malononitrile (4a) or ethyl cyanoacetate (4b) to give the 1,2-dihydropyridinederivatives 6a and 
6b, respectively, through the acyclic intermediates 5a,b. The structure of the latter products was 
based on analytical and spectral data. Thus, the 1H NMR spectrum of 6a showed the presence of 
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for the two phenyl groups and a singlet at  10.21 ppm  (D2O exchangeable) corresponding to 
the NH group. Moreover, the 13C NMR spectrum showed signal at 49.5 corresponding to the 
pyridine C-3,  two signals at 103.6, 104.5  for the C=C group, a signal at 119.5 for the CN 
group, eight signals at 120.19, 132.9, 125.8, 129.4, 129.5, 134.5, 136,8, 139.5 equivalent to 
two benzene and pyridine C and two signals at 165.9, 195.2  confirming the C=O and C=N 
groups. On the other hand, the reaction of compound 3 with either malononitrile or ethyl 
cyanoacetate in sodium ethoxide solution gave the 1,6-dihydropyridine derivatives 7a and 7b, 
respectively.  The reaction of compound 3 with the 2-aminoprop-1-ene-1,1,3-tricarbonitrile 8 
gave the 7,8-dihydro-1,8-naphthyridine derivative 9 (Scheme 1) its structure was confirmed on 
the basis of analytical and spectral data. 
The high yield of compound 7b encouraged us to make further work in order to produce 
pharmaceutically active fused pyridine derivatives. Thus, the reaction of compound 7b with 
either acetylacetone (10a) or ethyl acetoacetate (10b) gave the pyrido[2,3-c]pyridine derivatives 
11a and 11b, respectively. Furthermore, compound 7b reacted with either malononitrile or ethyl 
cyanoacetate to give the pyrido[2,3-c]pyridine derivatives 12a and 12b, respectively. The 
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R
Rafat M. Mohareb et al. 
Bull. Chem. Soc. Ethiop. 2020, 34(2) 
396
 
Scheme 3. Synthesis of compounds 16a,b; 19 and 20a-c. 
 
The benzoylbenzanilide was studied to synthesis thiophene through the well known 
Gewald’s thiophene synthesis [34, 35]. Thus, the reaction of compound 3 with elemental sulfur 
and either malononitrile (4a) and ethyl cyanoacetate (4b) gave the thiophene derivatives 13a 
and 13b, respectively (Scheme 2). On the other hand, compound 3 reacted with phenyl 
isothiocyanate in basic dimethylformamide gave the intermediate potassium sulphide salt 14. 
The latter intermediate reacted with either ethyl chloroacetate (15a) or chloroacetone (15b) to 
give the thiophene derivatives16a and 16b, respectively. The structures of the latter products 
were established on the basis of analytical and spectral data. Thus, the 1H NMR spectrum of 16a 
showed a triplet at 0.71 ppm indicating the presence of the ester CH3 group, a quartet at 3.87 
for the ester CH2 group, a mutiplet at  7.43-7.49 equivalent to the three phenyl protons and two 






14 + H2C COR
Cl
15a, R = OC2H5






16a, R = OC2H5













18 + X CHO
19a, X = H
    b, X = OCH3








20a, X = H
    b, X = OCH3
    c, X = Cl
Uses of -diketones for the synthesis of novel heterocyclic compounds  
Bull. Chem. Soc. Ethiop. 2020, 34(2) 
397
presence of  a signal at 13.6 for the CH3 group, a signal at 39.6 equivalent to the CH2 group 
and eleven signals at 110.0, 121.8, 125.8, 126.3, 128.4, 129.1, 130.4, 133.1, 138.0, 139.2, 
140.2, 148.7 indicating the two C6H5 and thiophene C and two signals at 165.8, 195.1 for the 
two C=O groups. 
Next we moved towards the uses of ethyl benzoylacetate to synthesis of benzimidazole 
derivatives. Thus, compound 1 reacted with orthophenylene diamine in an oil bath 120 oC to 
give the 2-(1H-benzo[d]imidazol-2-yl)-1-phenylethanone (18). The analytical and spectral data 
of compound 18 were in agreement with its proposed structure. Compound 18 reacted with 
either benzaldehyde (19a), 4-methoxybenzaldehyde (19b) or 4-chlorobenzaldehyde (19c) to 
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Compound 20a reacted with hydrazine hydrate to give the pyrazole derivative 21. On the 
other hand, 20b reacted with malononitrile (3a) to give the 1-amino-4-benzoyl-3-(4-
methoxyphenyl)benzo[4,5]imidazo[1,2-a]pyridine-2-carbonitrile (22). 
Compound 18 reacted with either benzenediazonium chloride (23a) or 4-
chlorobenzenediazonium chloride (23b) to give the phenylhydrazo derivative 24a and 24b, 
respectively. On the other hand, it reacted with malononitrile (3a) in 1,4-dioxane containing 
triethylamine to give the benzo[4,5]imidazo[1,2-a]pyridine derivative 25. Similarly compound 
18 reacted with either either acetylacetone (10a) or ethyl acetoacetate (10b) to give the 
benzo[4,5]imidazo[1,2-a]pyridine derivatives 26a and 26b, respectively (Scheme 4). 
 
Structure activity relationship  
 
From Table 1 the newly synthesized compounds were tested against the six cancer cell lines the 
human gastric cancer (NUGC), human colon cancer (DLD1), human liver cancer (HA22T and 
HEPG2), human breast cancer (MCF), nasopharyngeal carcinoma (HONE1) and a normal 
fibroblast cells (WI38). Compounds 6b, 7b, 9, 13a, 13b, 16a, 20b, 20c, 24b, 25 and 26b 
exhibited optimal cytotoxic effect against cancer cell lines, with IC50’s in the nM range. 
Comparing the cytotoxicity of the 1,2-dihydropyridine  derivatives 6a and 6b, it is obvious that 
the ethyl ester group present in 6b is responsible for its high cytotoxicity. On the other hand 
considering the 1,6-dihydropyridine 7a and 7b; the latter compound with the OH group showed 
high cytotoxicity against the  NUGC, DLDI, HA22T and HONE1 cell lines. The 2-(amino(6-
hydroxy-2-imino-1,4-diphenyl-1,2-dihydropyridin-3-yl)methylene)-malononitrile (9) showed 
high cytotoxicity against NUGC, DLDI and HEPG2 cell lines. Such high potency of compound 
9 is attributed to the presence of the dicyanethylidene moiety. Comparing the cytotoxicity of the 
1,6-naphthridine derivatives 11a and 11b, it is obvious that the presence of the OH group in 
compound 11b is responsible for its high cytotoxicity against HA22T and HEPG2 cell lines. 
Such finding was confirmed through the comparison of the cytotoxicity of compounds 12a and 
12b, where the last one showed higher cytotoxicity towards the six cancer cell lines. The 
significant cytotoxicity of 12b appeared against the HEPG2 cell line with 870 nM. 
For the thiophene derivatives 13a,b and 16a,b, it is clear from Table 1 that such compounds 
showed significant cytotoxicity against the cancer cell lines. Compounds 13b and 16a with the 
special optimal cytotoxicity which is attributed to the presence of the oxygen rich COOEt and 
OCH3 moeties in both compound, respectively. It is of great interest to compare the cytotoxicity 
of the un-substituted benzimidazole derivative 18 and the benzylidene derivatives 20a-c. It is 
obvious that compound 18 showed lower cytotoxicity relative to 20a-c. In addition going 
through the latter compounds, one can notice that the presence of the electronegative groups 
OCH3 and Cl in 20b and 20c, respectively are responsible for the high cytotoxicity of such 
compounds. Moreover, the Cl group showed more potency than the OCH3 group as cleared from 
the greater cytotoxicity of 20c over 20b. The annulated compound 22 showed higher 
cytotoxicity than the pyrazole derivative 21. The reaction of the benzimidazole derivative 18 
with arylidenediazonium salts 23a and 23b gave the arylhydrazone derivatives 24a and 24b  
leading to a remarkable increase of cytotoxicity of 24a,b. In addition compound 24b with Cl 
group showed an optimal cytotoxicity against NUGC, DLDI, HA22T, HEPG2 and MCF cell 
lines with IC50’s 380, 122, 33, 669 and 890 nM, respectively. It is of great value to note that 
compound 24b with the Cl group showed more potency than 24a. Considering the imidazo[1,2-
a]pyridine derivatives 25 and 26a,b compound 26b showed the highest cytotoxticity among the 
three compounds. Moreover, the nitrogen rich compound 25 showed higher cytotoxicity than 
26a. It is of good worthy to notice that the ethyl 6-hydroxy-2-imino-1,4-diphenyl-1,2-
dihydropyridine-3-carboxylate (6b) and the (1-hydroxy-3-methylbenzo[4,5]imidazo[1,2-
a]pyridine-4-yl)(phenyl)methanone (26b) showed the maximum inhibitory effect towards the 
six cancer cell lines among the tested compounds. 
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It is very clear from our present finding that the heterocyclic systems with halogen 
substituted pattern OCH3, Cl or COOEt show greater cytotoxic property. In every case it was 
observed that molecules with electronegative substitutions as compounds 6b, 7b, 13a,b; 16a,b; 
20b, 20c, 25, and 26b showed higher cytotoxicity because they were bearing either oxygen or 




It is well known that bioactive compounds are often toxic to shrimp larvae. Thus, in order to 
monitor these chemicals’ in vivo lethality to shrimp larvae (Artemia salina), results are given in 
Table 3 for the compounds which exhibited optimal cytotoxic effect against cancer cell lines 
which are the ten compounds 6b, 7b, 13a, 13b, 16a, 16b, 20b, 20c, 25 and 26b. The shrimp 
lethality assay is considered as a useful tool for preliminary assessment of toxicity, and it has 
been used for the detection of fungal toxins, plant extract toxicity, heavy metals, cyanobacteria 
toxins, pesticides, and cytotoxicity testing of dental materials, natural and synthetic organic 
compounds [36].  
 















































































Non toxic 1000.2 - - 
aTen organisms (A. salina) tested for each concentration. 
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In order to prevent the toxicity results from possible false effects originated from solubility 
of compounds and DMSO’s possible toxicity effect, compounds were prepared by dissolving in 
DMSO in the suggested DMSO volume ranges. It is clear from Table 3 that compounds 6b and 




The molecular studies were carried out using Molecular Operating Environment (MOE 2014). 
All the minimizations were performed with MOE until a RMSD gradient of 0.01 kcal/mol Å 
with MMFF94X force field and the partial charges were automatically calculated. Docking 
simulations were performed using the crystal structure of NUGC (PDB ID: 4ASD) which 
obtained from Protein Data Bank. Enzyme structure was checked for missing atoms, bonds and 
contacts. Water molecules was removed. Protonate 3D application of MOE was used to add the 
missing hydrogens and properly assign the ionization states. The ligand molecules were 
constructed using the builder molecule and were energy minimized. The active site was 
generated using the MOE-Alpha site finder. Ligands were docked within the active sites using 
the MOE-Dock The generated poses were energy minimized using the MMFF94x force field. 
Finally, the optimized poses were ranked using the GBVI/WSA DG free-energy estimates. 
Docking poses were visually inspected and interactions with binding pocket residues were 
analyzed. 
Docking simulation was carried out to illustrate the binding mode and the interaction of the 
active compounds 6b, 7b, 13a and 16b with the amino acids in the active site of the NUGC. 
Docking study was performed using the crystal structure of NUGC (PDB ID: 4ASD) [20] which 
has co-crystallized ligand (sorafenib, BAX) as inhibitor inside its active site. In the beginning, 
docking study was validated by re-docking of co-crystallized ligand (BAX) inside the active site 
of NUGC. The re-docking of the co-crystallized ligand, BAX, was carried out to indicate the 
suitability of the used protocol for the planned docking study. The validation method was 
achieved by removing the bound ligand from the complex followed by its docking back into the 
binding site, which yielded root mean square deviation values RMSD of 0.88 Å with energy 
score (S) -9.94 kcal/mol. The top pose obtained from the MOE docking simulation showed the 
interactions of the co-crystallized ligand, BAX, with the key amino acids inside the active site. 
Docking ligand interaction and electrostatic map of compounds 6b, 7b, 13a and 16b were 
indicated through Figures 2-5, respectively.  
 
 
                               (A)                                                                                  (B) 
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                                      (C) 
 
Figure 2. (A) Docking of compound 6b, (B) Ligand interaction of compound 6b, and (C) 
electrostatic map of compound 6b. Energy of compound 6b = -24.66. 
 
 
                                     (A)                                                                                (B)   
 
 
                                    (C) 
 
Figure 3. (A) Docking of compound 7b, (B) ligand interaction of compound 7b, and (C) 
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Figure 4. (A) Docking of compound 13a, (B) ligand interaction of compound 13a, and (C) 
electrostatic map of compound 13a. Energy of compound 13b = -24.89. 
 
 
(A)            (B) 
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Figure 5. (A) Energy of compound 16b, (B) ligand interaction of compound 16b, and (C) 
electrostatic map of compound 16b. Energy of compound 16b = -26.98. 
 
For Figures 2-5 the blue color indicating the structure of the target molecule and the green color 
for the amino acid. 
CONCLUSION 
 
The present work, through simple synthetic approaches, led to the development of novel 
pyridine, thiophene and imidazole derivatives that exhibited remarkable antitumor activities 
against six tumor cell lines. As new class of heterocyclic compounds, eleven of the obtained 
new compounds showed remarkable cytotoxicity against most of the six tumor cell lines. Most 
of the active compounds were devoid of the typical nitrogen and or sulfur feature of heterocyclic 
derivatives and so the activity could be attributed to some sort of electronegative substituents 
through the synthesized compounds. In addition c-Met kinase inhibitions for the most active 
compounds showed that all compounds exhibited inhibitions higher than the reference drug 
foretinib. The results of the biological screening will encourage future work of heterocyclic 
compounds derived from -diketones.  
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